Chongkundang - Asset Resilience Ratio
Chongkundang (001630) has an Asset Resilience Ratio of 6.45% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Chongkundang (001630) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2025)
This chart shows how Chongkundang's Asset Resilience Ratio has changed over time. See Chongkundang net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Chongkundang's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Chongkundang market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩108.21 Billion | 6.45% |
| Total Liquid Assets | ₩108.21 Billion | 6.45% |
Asset Resilience Insights
- Limited Liquidity: Chongkundang maintains only 6.45% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Chongkundang Industry Peers by Asset Resilience Ratio
Compare Chongkundang's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 1.28% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Procter & Gamble Health Limited
NSE:PGHL |
Drug Manufacturers - Specialty & Generic | 33.01% |
Annual Asset Resilience Ratio for Chongkundang (2000–2025)
The table below shows the annual Asset Resilience Ratio data for Chongkundang.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.26% | ₩36.77 Billion ≈ $24.92 Million |
₩1.63 Trillion ≈ $1.10 Billion |
+0.14pp |
| 2024-12-31 | 2.12% | ₩31.72 Billion ≈ $21.50 Million |
₩1.50 Trillion ≈ $1.01 Billion |
-0.35pp |
| 2023-12-31 | 2.47% | ₩35.96 Billion ≈ $24.37 Million |
₩1.46 Trillion ≈ $986.71 Million |
-0.94pp |
| 2022-12-31 | 3.41% | ₩46.87 Billion ≈ $31.76 Million |
₩1.38 Trillion ≈ $932.75 Million |
-1.35pp |
| 2021-12-31 | 4.76% | ₩65.07 Billion ≈ $44.10 Million |
₩1.37 Trillion ≈ $926.83 Million |
-0.77pp |
| 2020-12-31 | 5.53% | ₩69.57 Billion ≈ $47.15 Million |
₩1.26 Trillion ≈ $852.83 Million |
+0.54pp |
| 2019-12-31 | 4.99% | ₩53.59 Billion ≈ $36.32 Million |
₩1.07 Trillion ≈ $728.34 Million |
+1.37pp |
| 2018-12-31 | 3.62% | ₩31.52 Billion ≈ $21.36 Million |
₩871.44 Billion ≈ $590.56 Million |
-2.63pp |
| 2017-12-31 | 6.24% | ₩51.12 Billion ≈ $34.65 Million |
₩818.86 Billion ≈ $554.93 Million |
+2.76pp |
| 2016-12-31 | 3.48% | ₩24.59 Billion ≈ $16.66 Million |
₩705.67 Billion ≈ $478.22 Million |
-0.51pp |
| 2015-12-31 | 3.99% | ₩20.00 Billion ≈ $13.55 Million |
₩501.01 Billion ≈ $339.52 Million |
-1.67pp |
| 2014-12-31 | 5.66% | ₩17.13 Billion ≈ $11.61 Million |
₩302.66 Billion ≈ $205.11 Million |
-0.85pp |
| 2013-12-31 | 6.51% | ₩18.06 Billion ≈ $12.24 Million |
₩277.52 Billion ≈ $188.07 Million |
+0.54pp |
| 2012-12-31 | 5.96% | ₩42.21 Billion ≈ $28.61 Million |
₩708.02 Billion ≈ $479.81 Million |
+2.55pp |
| 2011-12-31 | 3.41% | ₩23.03 Billion ≈ $15.61 Million |
₩675.48 Billion ≈ $457.77 Million |
+2.66pp |
| 2010-12-31 | 0.75% | ₩4.16 Billion ≈ $2.82 Million |
₩553.85 Billion ≈ $375.33 Million |
-1.00pp |
| 2009-12-31 | 1.75% | ₩8.05 Billion ≈ $5.46 Million |
₩460.21 Billion ≈ $311.88 Million |
-0.30pp |
| 2008-12-31 | 2.04% | ₩9.21 Billion ≈ $6.24 Million |
₩450.57 Billion ≈ $305.34 Million |
-0.44pp |
| 2007-12-31 | 2.49% | ₩10.26 Billion ≈ $6.95 Million |
₩412.01 Billion ≈ $279.22 Million |
-0.25pp |
| 2006-12-31 | 2.74% | ₩10.85 Billion ≈ $7.35 Million |
₩396.56 Billion ≈ $268.75 Million |
+0.94pp |
| 2005-12-31 | 1.80% | ₩6.41 Billion ≈ $4.35 Million |
₩356.98 Billion ≈ $241.92 Million |
-2.56pp |
| 2004-12-31 | 4.36% | ₩14.47 Billion ≈ $9.80 Million |
₩332.05 Billion ≈ $225.02 Million |
-2.32pp |
| 2003-12-31 | 6.68% | ₩26.28 Billion ≈ $17.81 Million |
₩393.38 Billion ≈ $266.59 Million |
+0.03pp |
| 2002-12-31 | 6.65% | ₩27.97 Billion ≈ $18.95 Million |
₩420.64 Billion ≈ $285.06 Million |
-4.36pp |
| 2001-12-31 | 11.01% | ₩53.66 Billion ≈ $36.36 Million |
₩487.37 Billion ≈ $330.29 Million |
+3.68pp |
| 2000-12-31 | 7.33% | ₩42.64 Billion ≈ $28.89 Million |
₩581.68 Billion ≈ $394.20 Million |
-- |
About Chongkundang
Chong Kun Dang Holdings Corp. manufactures and distributes pharmaceutical products in South Korea and internationally. Chong Kun Dang Holdings Corp. was founded in 1941 and is based in Seoul, South Korea.